Citation Impact
Citing Papers
Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates
2010
Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge
2009
Spontaneous tumor rejection by cbl-b –deficient CD8+ T cells
2007
Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial
2009
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice
2009
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries
2006
Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritisSafety and immunogenicity
2006
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Needle-free influenza vaccination
2010
Crystal Structure of the HSV-1 Fc Receptor Bound to Fc Reveals a Mechanism for Antibody Bipolar Bridging
2006 StandoutNobel
Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays—an update
2006
Better Neutralization of Herpes Simplex Virus Type 1 (HSV-1) Than HSV-2 by Antibody From Recipients of GlaxoSmithKline HSV-2 Glycoprotein D2 Subunit Vaccine
2014
Infections and cancer: Established associations and new hypotheses
2008
Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1
2000 Standout
Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries
2005
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Vaccines to prevent genital herpes
2020
Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
2006
Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
2010
Human papillomavirus oncoproteins: pathways to transformation
2010 Standout
Immune responses to human papillomavirus
2005
Two-photon polymerization of microneedles for transdermal drug delivery
2010
The biology and management of non-small cell lung cancer
2018 StandoutNature
Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults
2008
Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes
2006
An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs
2017
Cervical Coinfection with Human Papillomavirus (HPV) Types and Possible Implications for the Prevention of Cervical Cancer by HPV Vaccines
2005
Dose sparing enabled by skin immunization with influenza virus-like particle vaccine using microneedles
2010
Chapter 16: HPV vaccines in immunocompromised women and men
2006
Dense display of HIV-1 envelope spikes on the lambda phage scaffold does not result in the generation of improved antibody responses to HIV-1 Env
2011
Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study
2009
Antibody Responses to Hepatitis A Virus Vaccine in HIV‐Infected Children with Evidence of Immunologic Reconstitution while Receiving Highly Active Antiretroviral Therapy
2005
Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions
2007
Beyond Cervical Cancer: Burden of Other HPV-Related Cancers Among Men and Women
2010
Concatenated Multitype L2 Fusion Proteins as Candidate Prophylactic Pan-Human Papillomavirus Vaccines
2009
Induction of mucosal immunity through systemic immunization: Phantom or reality?
2016
The global health burden of infection‐associated cancers in the year 2002
2006 Standout
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases
2006
Stabilization of Influenza Vaccine Enhances Protection by Microneedle Delivery in the Mouse Skin
2009
Hepatitis A and B Vaccination Practices for Ambulatory Patients Infected with HIV
2004
Human papillomavirus types among women infected with HIV: a meta-analysis
2006
Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women
2013
Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles
2010
Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012
2015
Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled Trial
2008
Long-term Durability of Immune Responses After Hepatitis A Vaccination Among HIV-Infected Adults
2011
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
2007 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Viral interference with antibody and complement
1998
A Strategy for O-Glycoproteomics of Enveloped Viruses—the O-Glycoproteome of Herpes Simplex Virus Type 1
2015
Antibody responses to crucial functional epitopes as a novel approach to assess immunogenicity of vaccine adjuvants
2019
HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
1993 StandoutNature
Characterization of the Interaction between the Herpes Simplex Virus Type I Fc Receptor and Immunoglobulin G
1999
Virus‑like particles as a vaccine delivery system: Myths and facts
2008
Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection
1990
Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults
2008
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11
2006
Pancreatic Adenocarcinoma
2014 Standout
Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system
2007
A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial
2008
Global cancer statistics
2011 Standout
Next generation vaccines and vectors: Designing downstream processes for recombinant protein‐based virus‐like particles
2015
Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region
2006
Goose parvovirus structural proteins expressed by recombinant baculoviruses self-assemble into virus-like particles with strong immunogenicity in goose
2011
Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults
2007
ANTIBODY RESPONSES TO HEPATITIS A VIRUS VACCINATION IN THAI HIV-INFECTED CHILDREN WITH IMMUNE RECOVERY AFTER ANTIRETROVIRAL THERAPY
2010
Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity
2009
Formulation of Microneedles Coated with Influenza Virus-like Particle Vaccine
2010
Skin Vaccination against Cervical Cancer Associated Human Papillomavirus with a Novel Micro-Projection Array in a Mouse Model
2010
Human papillomavirus and cervical cancer
2007 Standout
Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement
2011
Case–Control Study of Human Papillomavirus and Oropharyngeal Cancer
2007 Standout
Microneedle-Based Vaccines
2009
Immunity, Inflammation, and Cancer
2010 Standout
Transient expression of Human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector
2006
The Herpes Simplex Virus-1 Glycoprotein E (gE) Mediates IgG Binding and Cell-to-Cell Spread through Distinct gE Domains
1997
Improved influenza vaccination in the skin using vaccine coated microneedles
2009
HPV-FASTER: broadening the scope for prevention of HPV-related cancer
2015
Safety and Immunogenicity of an Inactivated Hepatitis A Vaccine among HIV-Infected Subjects
2004
Cervical Cancer Screening Rates in the United States and the Potential Impact of Implementation of Screening Guidelines
2007
Transient expression of Human papillomavirus type 16 L2 epitope fused to N- and C-terminus of coat protein of Potato virus X in plants
2012
Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines
2010
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Vaccine manufacturing: challenges and solutions
2006
Cancer immunotherapy comes of age
2011 StandoutNature
Immunogenicity Testing in Human Papillomavirus Virus‐Like‐Particle Vaccine Trials
2009
Microneedle arrays as medical devices for enhanced transdermal drug delivery
2011
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
2008
Role of Viral Load in Heterosexual Transmission of Human Immunodeficiency Virus Type 1 by Blood Transfusion Recipients
1997
Efficacy of Human Papillomavirus Vaccines
2009
Complement
2001 Standout
Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab
2012
Dual-strain genital herpes simplex virus type 2 (HSV-2) infection in the US, Peru, and 8 countries in sub-Saharan Africa: A nested cross-sectional viral genotyping study
2017
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial
2009
Human papillomavirus type distribution in invasive cervical cancer and high‐grade cervical lesions: A meta‐analysis update
2007 Standout
Modified Tobacco mosaic virus particles as scaffolds for display of protein antigens for vaccine applications
2006
Synthesis and Microcontact Printing of Dual End‐Functionalized Mucin‐like Glycopolymers for Microarray Applications
2009 StandoutNobel
Microneedles for drug and vaccine delivery
2012 Standout
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
2010
Clonal evolution in cancer
2012 StandoutNature
Design of therapeutic vaccines: hepatitis B as an example
2011
Enhanced Memory Responses to Seasonal H1N1 Influenza Vaccination of the Skin with the Use of Vaccine‐Coated Microneedles
2009
DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge
2010
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
Immune escape by Epstein–Barr virus associated malignancies
2008
Human papillomavirus infection and the primary and secondary prevention of cervical cancer
2008
Cost-effectiveness analyses of human papillomavirus vaccination
2007
Click Chemistry In Situ: Acetylcholinesterase as a Reaction Vessel for the Selective Assembly of a Femtomolar Inhibitor from an Array of Building Blocks
2002 StandoutNobel
Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice
2008
Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus
2008
Improved DNA vaccination by skin-targeted delivery using dry-coated densely-packed microprojection arrays
2010
An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock
2008
Human Papillomavirus Infection in Solid Organ Transplant Recipients
2009
Cancer as an evolutionary and ecological process
2006 Standout
pH Dependence and Stoichiometry of Binding to the Fc Region of IgG by the Herpes Simplex Virus Fc Receptor gE-gI
2004
Dissolving polymer microneedle patches for influenza vaccination
2010
CCR5 Genotypes in Sexually Active Couples Discordant for Human Immunodeficiency Virus Type 1 Infection Status
1997
Therapeutic immunisation of rabbits with cottontail rabbit papillomavirus (CRPV) virus-like particles (VLP) induces regression of established papillomas
2008
Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination
2006
Randomized Controlled Trial of High-Dose Intradermal Versus Standard-Dose Intramuscular Influenza Vaccine in Organ Transplant Recipients
2013
Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors
2005
SARS-CoV-2 vaccines in development
2020 StandoutNature
Global Estimates of Prevalent and Incident Herpes Simplex Virus Type 2 Infections in 2012
2015
Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine Treatment
1994 Standout
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Expression of Human papillomavirus 16 E7ggg oncoprotein on N- and C-terminus of Potato virus X coat protein in bacterial and plant cells
2011
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever
2010
Chimeric L1-L2 Virus-Like Particles as Potential Broad-Spectrum Human Papillomavirus Vaccines
2009
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
2007 Standout
Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant
2009 StandoutNobel
Microneedle-Based Intradermal Delivery of the Anthrax Recombinant Protective Antigen Vaccine
2006
The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
2007 Science
Immunization with a Vaccine Combining Herpes Simplex Virus 2 (HSV-2) Glycoprotein C (gC) and gD Subunits Improves the Protection of Dorsal Root Ganglia in Mice and Reduces the Frequency of Recurrent Vaginal Shedding of HSV-2 DNA in Guinea Pigs Compared to Immunization with gD Alone
2011
A Replication-Competent, Neuronal Spread-Defective, Live Attenuated Herpes Simplex Virus Type 1 Vaccine
2008
Direct evidence for antibody bipolar bridging on herpes simplex virus-infected cells.
1992
Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer
2007
New Approaches to Immunotherapy for HPV Associated Cancers
2011
Immune evasion by herpes simplex virus type 1, strategies for virus survival.
2003
HPV vaccination: the promise & problems.
2009
Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection
2009
HPV Vaccination and the Risk of Invasive Cervical Cancer
2020
Blocking Herpes Simplex Virus 2 Glycoprotein E Immune Evasion as an Approach To Enhance Efficacy of a Trivalent Subunit Antigen Vaccine for Genital Herpes
2014
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious Mononucleosis
2007
Intracellular Traffic of Herpes Simplex Virus Glycoprotein gE: Characterization of the Sorting Signals Required for Itstrans-Golgi Network Localization
1999
Plant-Produced Cottontail Rabbit Papillomavirus L1 Protein Protects against Tumor Challenge: a Proof-of-Concept Study
2006
Cancer statistics in China, 2015
2016 Standout
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A
2011 StandoutNobel
Mucosal Administration of CpG Oligodeoxynucleotide Elicits Strong CC and CXC Chemokine Responses in the Vagina and Serves as a Potent Th1-Tilting Adjuvant for Recombinant gD2 Protein Vaccination against Genital Herpes
2006
A Direct Comparison of Human Papillomavirus Type 16 L1 Particles Reveals a Lower Immunogenicity of Capsomeres than Viruslike Particles with Respect to the Induced Antibody Response
2008
Human Dendritic Cells Activate Resting Natural Killer (NK) Cells and Are Recognized via the NKp30 Receptor by Activated NK Cells
2002 StandoutNobel
Maternal immunization confers protection against neonatal herpes simplex mortality and behavioral morbidity
2019
The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex
2009 StandoutNature
An N-Terminal Domain of Herpes Simplex Virus Type I gE Is Capable of Forming Stable Complexes with gI
2001
Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model
2015
Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees
2007
An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection
2020 StandoutNobel
Carboxymethylcellulose–Chitosan‐coated microneedles with modulated hydration properties
2011
Vaccines to Prevent Infections by Oncoviruses
2010
Maternal Antiviral Immunoglobulin Accumulates in Neural Tissue of Neonates To Prevent HSV Neurological Disease
2017
Protective Immunity in Mice Achieved with Dry Powder Formulation and Alternative Delivery of Plague F1-V Vaccine
2009
Cancer statistics, 2016
2016 Standout
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2
2008
A Virus-Like Particle-Based Epstein-Barr Virus Vaccine
2011
Priming of protective T cell responses against virus-induced tumors in mice with human immune system components
2009 StandoutNobel
The Herpes Simplex Virus 1 IgG Fc Receptor Blocks Antibody-Mediated Complement Activation and Antibody-Dependent Cellular CytotoxicityIn Vivo
2011
Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions
2007
Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection
2020
Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization
2010
Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies
2008
The global and regional burden of genital ulcer disease due to herpes simplex virus: a natural history modelling study
2020
Viral Subversion of the Immune System
2000
Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2
2007
Short Interfering RNA-Mediated Inhibition of Herpes Simplex Virus Type 1 Gene Expression and Function during Infection of Human Keratinocytes
2004 StandoutNobel
In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc
1999
Epstein-Barr virus vaccine development: a lytic and latent protein cocktail
2008
Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries
2005
Novel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1
2000
Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses
2008 StandoutNobel
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
2013 Standout
Virus-like particles: flexible platforms for vaccine development
2007
Safety and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab
2012
Global cancer statistics, 2012
2015 Standout
Herpes Simplex Virus Type 1 and 2 Glycoprotein C Prevents Complement-Mediated Neutralization Induced by Natural Immunoglobulin M Antibody
2006
Polyvalente Wechselwirkungen in biologischen Systemen: Auswirkungen auf das Design und die Verwendung multivalenter Liganden und Inhibitoren
1998
Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization
2007
Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan
2007
Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization
2009
Vaccines: the Fourth Century
2009
Trivalent Glycoprotein Subunit Vaccine Prevents Neonatal Herpes Simplex Virus Mortality and Morbidity
2020
Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook
2008
Vaccination of Healthy Volunteers with Human Papillomavirus Type 16 L2E7E6 Fusion Protein Induces Serum Antibody that Neutralizes across Papillomavirus Species
2006
Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes
2019 StandoutNobel
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
2007
Herpes Simplex Virus Type 1 Glycoprotein E Domains Involved in Virus Spread and Disease
2000
Herpes Simplex Virus Type 1 Glycoprotein E Is Required for Axonal Localization of Capsid, Tegument, and Membrane Glycoproteins
2005
Chemical Glycoproteomics
2016 StandoutNobel
The Extracellular Domain of Herpes Simplex Virus gE Is Indispensable for Efficient Cell-to-Cell Spread: Evidence for gE/gI Receptors
2005
Responses of Herpes Simplex Virus Type 1-Infected Cells to the Presence of Extracellular Antibodies: gE-Dependent Glycoprotein Capping and Enhancement in Cell-to-Cell Spread
2002
Works of Gary Dubin being referenced
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
2004
Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes
2002
Immunization of Early Adolescent Females with Human Papillomavirus Type 16 and 18 L1 Virus-Like Particle Vaccine Containing AS04 Adjuvant
2007
Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine
2013
Efficacy Results of a Trial of a Herpes Simplex Vaccine
2012
Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial
2015
Safety and Immunogenicity of Glycoprotein D--Adjuvant Genital Herpes Vaccine
2005
The Role of Herpes Simplex Virus Glycoproteins in Immune Evasion
1992
Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines
2008
Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses☆
2009
Safety and Immunogenicity of Hepatitis A Vaccine in Human Immunodeficiency Virus–Infected Patients: A Double‐Blind, Randomized, Placebo‐Controlled Trial
2003
Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
2006
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection
2007
Epidemiology, Clinical Presentation, and Antibody Response to Primary Infection With Herpes Simplex Virus Type 1 and Type 2 in Young Women
2012
Efficacy of the HPV-16/18 vaccine: Final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial
2014
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 Years
2008
Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults
2007
Serum Antibody Responses after Intradermal Vaccination against Influenza
2004
Failure of Culture and Polymerase Chain Reaction to Detect Human Immunodeficiency Virus (HIY) in Seronegative Steady Sexual Partners of HIV-Infected Individuals
1995
Comparison of the immunogenicity and safety ofCervarix™ andGardasil®human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18–45 years
2009
Zidoyudine-Induced Hepatotoxicity
1989
Characterization of regions of herpes simplex virus type 1 glycoprotein E involved in binding the Fc domain of monomeric IgG and in forming a complex with glycoprotein I.
1995
Herpes simplex virus type 1 encodes two Fc receptors which have different binding characteristics for monomeric immunoglobulin G (IgG) and IgG complexes
1990
Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial
2005
Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity
1991
Mapping regions of herpes simplex virus type 1 glycoprotein I required for formation of the viral Fc receptor for monomeric IgG.
1997
Characterization of domains of herpes simplex virus type 1 glycoprotein E involved in Fc binding activity for immunoglobulin G aggregates
1994
Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing
2006
In Vivo Immune Evasion Mediated by the Herpes Simplex Virus Type 1 Immunoglobulin G Fc Receptor
1998